Document Detail


Challenges with advanced therapy medicinal products and how to meet them.
MedLine Citation:
PMID:  20190786     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products, are at the cutting edge of innovation and offer a major hope for various diseases for which there are limited or no therapeutic options. They have therefore been subject to considerable interest and debate. Following the European regulation on ATMPs, a consolidated regulatory framework for these innovative medicines has recently been established. Central to this framework is the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA), comprising a multidisciplinary scientific expert committee, representing all EU member states and European Free Trade Association countries, as well as patient and medical associations. In this article, the CAT discusses some of the typical issues raised by developers of ATMPs, and highlights the opportunities for such companies and research groups to approach the EMA and the CAT as a regulatory advisor during development.
Authors:
; ; Christian K Schneider; Paula Salmikangas; Bernd Jilma; Bruno Flamion; Lyubina Racheva Todorova; Anna Paphitou; Ivana Haunerova; Toivo Maimets; Jean-Hugues Trouvin; Egbert Flory; Asterios Tsiftsoglou; Bal?zs Sarkadi; Kolbeinn Gudmundsson; Maura O'Donovan; Giovanni Migliaccio; J?nis Anc?ns; Romaldas Maciulaitis; Jean-Louis Robert; Anthony Samuel; Johannes H Ovelg?nne; Marit Hystad; Andrzej Mariusz Fal; Beatriz Silva Lima; Anca Stela Moraru; Peter Turc?ni; Robert Zorec; Sol Ruiz; Lennart Akerblom; Gopalan Narayanan; Alastair Kent; Fabrizia Bignami; J George Dickson; Dietger Niederwieser; Mar?a-Angeles Figuerola-Santos; Ilona G Reischl; Claire Beuneu; Rosen Georgiev; Maria Vassiliou; Alena Pychova; Mette Clausen; Taina Methuen; Sophie Lucas; Martina Sch?ssler-Lenz; Vasilios Kokkas; Zsuzsanna Buz?s; Niall MacAleenan; Maria Cristina Galli; Aija Lin?; Jolanta Gulbinovic; Guy Berchem; Mariusz Fraczek; Margarida Menezes-Ferreira; Nela Vilceanu; Mikul?s Hrubisko; Petra Marinko; Marcos Tim?n; Wing Cheng; George Andrew Crosbie; Nick Meade; Michelino Lipucci di Paola; Thierry VandenDriessche; Per Ljungman; Lucia D'Apote; Olga Oliver-Diaz; Isabel B?ttel; Patrick Celis
Related Documents :
16547146 - Sailing and sports medicine: a literature review.
12828716 - Examination for the certificate in advanced practice in cervical cytology--the first ye...
18022586 - Impact of the us patent system on the promise of personalized medicine.
1367866 - Antisense technology.
15049296 - A jewish argument for socialized medicine.
21310056 - Canadian clinical practice guidelines for acute and chronic rhinosinusitis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  9     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-01     Completed Date:  2010-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  195-201     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
European Union
Gene Therapy / legislation & jurisprudence*,  methods
Government Regulation*
Humans
Stem Cell Transplantation / legislation & jurisprudence*,  methods
Tissue Engineering / legislation & jurisprudence*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ferroelastic switching for nanoscale non-volatile magnetoelectric devices.
Next Document:  Membrane transporters in drug development.